~~<i id='FAB49B5360'><strike id='FAB49B5360'><tt id='FAB49B5360'><pre id='FAB49B5360'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

knowledge

author：fashion 2025-10-02 14:03:17 - browse：15

Two business miniatures talk to each other on coin stacks that are sandwiched by a syringe and a stethoscope — coverage from STAT — Adobe

For all the flak they get, the country’s four biggest pharmacy benefit managers reported a surprisingly tame average profit margin in the first three quarters of 2023: 4.5%, less than a third of their drugmaker peers.

But don’t take their numbers as gospel, experts warned.

“It’s really easy to move money around inside the books of a vertically integrated organization,” said Karen Van Nuys, a senior fellow at the USC Schaeffer Center for Health Policy and Economics. “If one segment of your vertically integrated organization is not publishing any financial data, it’s a good place to hide stuff.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： STAT Summit: Meghan O’Rourke on making chronic illness visible

focus

knowledge

focus

entertainment

focus

AdobeYou’rereadingthewebeditionofHealthCareInc.,STAT’sweeklynewsletterfollowingtheflowofmoneythrough

WSS

Shingles, which affected Dianne Feinstein, is on the rise

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Merck, Daiichi strike cancer drug pact worth up to $22 billion

ADCs take center stage as promising cancer treatments

FDA clears Verve to begin U.S. study of gene

Readout LOUD podcast: Live from the 2023 STAT Summit

hotspot

knowledge

focus

Tori Bowie and the unacceptable rates of Black maternal death

Roivant's CEO is a star, but biotech's black hole persists

Sports medicine is finally prioritizing gender equality

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Apple is now the first public company to be valued at $3 trillion

Menendez indictment could see pharma lose a key ally

Medicare proposal to cover medical devices draws a mixed reaction

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Moonlake's readout produced a cash windfall. Risks remain

Merck, Daiichi strike cancer drug pact worth up to $22 billion

knowledge

Health tech investors get more selective as pandemic boom fades

UnitedHealth, Optum discontinue NaviHealth name

Smaller biotechs seek to piggyback on weight loss drug boom

Smaller biotechs seek to piggyback on weight loss drug boom

Medicare drug price negotiation program allowed for now

STAT Readout Newsletter: Biotech news today

focus

focus

entertainment

focus